Abstract:Abstract Introduction :Extranodal NK/T-cell lymphoma, nasal type (NKTCL) is an aggressive subtype of non-Hodgkin lymphoma that is characterized by extranodal presentation. Central nervous system (CNS) involvement in NKTCL is very rare and carries dismal outcome, but lacks clear consensus on optimal treatment. This study summarized the clinicopathological features, treatment patterns and survival outcomes of NKTCL patients with CNS involvement, in order to improve the understanding of CNS involvement in NKTCL. Methods: 1019 patients diagnosed with extranodal NKTCL, from August 2010 to January 2021 were reviewed, and patients with CNS involvement were included in the analysis. The CNS involvement was diagnosed either pathologically or clinically. Due to the difficulties and potential hazards of brain biopsy, pathologic confirmation of CNS involvement was conducted by identifying malignant cells in the cerebrospinal fluid (CSF) by cytology and flow cytometry analysis. Clinically diagnosed CNS involvement was based upon the characteristic radiographic findings by magnetic resonance imaging (MRI), computed tomography (CT) or positron emission tomography (PET/CT), Circulating EBV-DNA was detected by quantitative polymerase chain reaction (PCR). Overall survival (OS) was defined as time from confirmation of CNS disease to death from any cause or last follow up. Results: Among 1019 patients diagnosed with NKTCL, 14 cases (1.3%) with CNS involvement were included. The general characteristics of these patients are listed in Table 1. Of these 14 patients, the median age was 40.5 years (range, 14-57 years) at the time of diagnosis of CNS involvement. Approximately 71.4%(10/14)of patients were men. The median time between initial diagnosis of NKTCL and diagnosis of CNS involvement was 3.0 months (range, 0-141.0 months). 5 patients suffered CNS involvement at initial diagnosis of NKTCL. The other 9 CNS involvement were identified as disease progression. All patients underwent radiological examination, which disclosed the lesion location in CNS of 9 patient. The other 5 patients were diagnosed with CNS involvement by the examination of CSF. The elevated protein concentration and leukocytosis in CSF were identified in 8 and 2 patients, respectively. Among these patients with CNS involvement, the median number of treatment lines after the diagnosis of CNS involvement was 1.5 (range, 1-4). The best response was complete response (CR) in 11 patients, partial response (PR) in 1 patient, stable disease in 1 patient and progressive disease in 1 patient. CR was achieved when patients were treated with pegaspargase- containing regimens(n=4), anti-PD-1 antibodies-containing regimens(n=3), chidamide-containing regimens(n=2) and HD-MTX-containing regimens(n=2). After achieving CR, 2 patients received anti-PD-1 antibodies as maintenance treatment, with the duration of response of 26 and 72 months, respectively. With the median follow-up of 24.5 months (range, 4-72 months), 5 patients died of NKTCL, and the median OS was not reached. 9 patients presented with high circulating EBV-DNA level at diagnosis of CNS involvement, and the post-treatment EBV-DNA descended to the normal level in 7 patients, among whom 6 patients achieved CR. Conclusions: The incidence of CNS involvement in NKTCL is low. Compared with previous studies, more patients received anti-PD-1 antibodies- and chidamide-containing regimens, which may contribute to the improved response rate and survival outcomes. Measurement of dynamic changes in EBV-DNA levels during the treatment process can be applied to monitor the treatment response. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG)

Effects of Core Needle Biopsy and Subsequent Neoadjuvant Chemotherapy on Molecular Alterations and Outcome in Breast Cancer

Risk‐based, response‐adapted therapy for early‐stage extranodal nasal‐type NK /T‐cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study

First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG

Patterns of Primary Tumor Invasion and Regional Lymph Node Spread Based on Magnetic Resonance Imaging in Early-Stage Nasal NK/T-cell Lymphoma: Implications for Clinical Target Volume Definition and Prognostic Significance

Clinical Features, Prognostic Stratification, and Treatment of Advanced-Stage Non-Nasal Type Extranodal Natural Killer/t-Cell Lymphoma: a Multi-Institutional Real-World Study.

Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making

Prognostic Factors and Treatment Outcomes for Patients with Stage II Extranodal Nasal-Type Natural Killer/t-Cell Lymphoma of the Upper Aerodigestive Tract

Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a single medical center

Treatment Outcomes and Prognostic Factors of Chemotherapy Combined with Radiation Therapy for Patients with Early-Stage Extranodal Natural Killer/T-Cell Lymphoma.

[Value of PET/CT in the prognosis of extranodal NK/T cell lymphoma]

Association between radiographic and clinicopathological features and prognosis in patients with extranodal NK/T cell lymphoma

Clinicopathologic Features and Treatment Outcome of Primary Intestinal Non-Hodgkin Lymphoma: A Single Center Experience.

Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin

The prognostic role of level of involved regional lymph node in patients with stage Ⅱ extranodal nasal-type NK/T-cell lymphoma of the upper aerodigestive tract

Survival advantage with the addition of radiation therapy to chemotherapy in early stage peripheral T-cell lymphoma, not otherwise specified.

Characteristics and Prognosis of Distant Metastasis after Primary Treatment for Early-Stage Extranodal Nasal-Type Natural Killer/t-Cell Lymphoma from the China Lymphoma Collaborative Group Database.

Efficacy and toxicities of chemoradiotherapy in the treatment of early stage extranodal nasal-type NK/T-cell lymphoma

The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients

Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group

Central Nervous System Involvement in Extranodal Natural Killer/T-Cell Lymphoma: Case Series